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Abstract
Introduction. The problem of lead-induced tricuspid regurgitation (LITR) in patients with arrhythmogenic right ventricular 
cardiomyopathy (ARVC) is poorly investigated. Patients with high risk of adverse outcome usually receive implantable 
cardioverter-defibrillator (ICD) as a prevention of sudden cardiac death (SCD). Unfortunately, the insertion of ICD into 
the right ventricle is supposed to exacerbate tricuspid regurgitation.
As ICD (or cardiac resynchronization therapy defibrillator) seems to be necessity in prevention of SCD in quite large group 
of patients, we aimed to evaluate frequency of LITR and further outcome in these persons.
Material and methods. In a database of 55 patients with ARVC and ICD implanted in prevention of SCD, we selected 
35 patients (mean age 48.78 ± 13.56 years) with data suitable for analysis. Based on the results of echocardiography, 
study population was divided into 2 groups: TR+ group with worsening of tricuspid regurgitation (TR) defined as its de-
terioration to higher grade and TR– group (without worsening of TR).
Results. In 65.71% of patients TR worsened after ICD implantation. Mean time of observation was 91.06 ± 55.32 months. 
In TR+ group, 2 patients (8.7%) died because of heart failure and 1 patient died in a traffic accident. In TR– group 1 patient 
(8.33%) died because of heart failure and 1 patient had heart transplantation (results were statistically insignificant).
Conclusions. We couldn’t prove that the worsening of TR was associated with worsening of clinical outcome. Further 
studies are needed to assess an influence of LITR on prognosis in patients with ARVC and ICD implanted.
Key words: arrhythmogenic right ventricular cardiomyopathy, tricuspid regurgitation, implantable cardioverter-defibrillator, 
sudden cardiac death
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Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 
is an inheritable disease characterized by progressive 
fibrofatty replacement of the cardiac muscle. Its estimated 
prevalence is 1:2,500–1:5,000 [1]. Molecular studies pro-
ve that ARVC is mainly a disease of intercellular junctions 
[2]. Heterogenic mutations have been found in different 
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proteins responsible for cell-to-cell adhesion, resulting in 
detachment of the cardiomyocytes and their susceptibility 
to mechanical stress.
Clinical manifestations in ARVC are typically associated 
with the right ventricle (RV), although involvement of the left 
ventricle (LV) is not rare. Classical features of the disease 
are RV dilatation and RV regional or global systolic dysfun-
ction [3]. Progressive RV dilatation may lead to secondary 
worsening of tricuspid regurgitation (TR), which contributes 
to further decrease in RV stroke volume [4].
Clinical presentation of ARVC consists of palpitations 
(66.9% pts), syncope (32.3% pts), atypical chest pain 
(26.9% pts), dyspnea (10.8% pts) and clinical signs of right 
ventricular failure (6.2% pts) [5]. In some cases the first 
symptom of the disease is sudden cardiac death (SCD) [6].
Patients with high risk of adverse outcome usually 
receive implantable cardioverter-defibrillator (ICD) as 
a prevention of SCD. Unfortunately, the insertion of ICD 
into the right ventricle is supposed to exacerbate tricuspid 
regurgitation. Significant tricuspid regurgitation, according 
to the recent research, may negatively affect prognosis in 
patients with ARVC [4]. However, up to the present moment 
the risk of TR progression after ICD implantation and its 
possible consequences in patients with ARVC have not 
been fully established.
The aim of our study was to assess the progression of 
TR and its clinical outcome in a group of high-risk patients 
with ARVC who underwent ICD implantation.
Material and methods
Study population consisted of 35 patients (pts) out of 55 
pts with ARVC and ICD implanted in primary as well as in 
secondary prevention. Twenty pts were excluded because 
of incomplete data. Secondary prevention was provided 
to patients with a history of cardiac arrest, hemodynami-
cally unstable ventricular tachycardia and syncope. The 
enrollment criteria were: a confirmed diagnosis of ARVC 
(according to the Revised Task Force Criteria published 
in 2010), implanted ICD and complete echocardiographic 
data. All data collected between 1995 and 2014 came 
from medical registry of the Institute of Cardiology. These 
included: clinical presentation before implantation of the 
ICD, family history, ECG and 24-hour Holter recordings, 
antiarrhythmic agents used, echocardiography data, infor-
mation about ICD interventions.
The group consisted of 29 males (83%) and 6 females, 
mean age 48.78 ± 13.56 years (ranging from 26 to 71). 
Seventeen (48.57%) patients had signs and symptoms 
of heart failure before ICD implantation, twelve (34.29%) 
patients had a history of regular sport activity before 
that procedure. Family history of ARVC was reported in 
9 pts (25.71%). Mean time of observation was 91.06 ± 
± 55.32 months.
All patients were given appropriate treatment for 
arrhythmias, heart failure and concomitant afflictions 
such as major depressive disorder or generalized anxiety 
disorder.
The ICD was implanted in primary — 24 (68.57%) and 
secondary — 11 (31.43%) prevention of SCD. The mean age 
at ICD implantation was 39.89 ± 13.90 years.
Eight pts (22.86%) had implanted cardiac pacemaker 
before implantation of ICD. Moreover, in case of 4 patients 
cardiac resynchronization therapy (CRT-D) was used accor-
ding to clinical indications.
Sixteen (48.48%) pts underwent radiofrequency abla-
tion of arrhythmia substrate.
Data of general population are collected in Table 1.
Echocardiography
Transthoracic echocardiography (TTE) was performed using 
ultrasound transducers Vivid 6, Vivid 7 and Sonos 5500 
to estimate TR and other parameters such as ejection 
fraction of the left ventricle, PLAX RVOT (parasternal long 
axis right ventricular outflow tract) and TAPSE (tricuspid 
annular plane systolic excursion).
Echocardiographic examinations were performed be-
fore and after ICD implantation. The mean time from ICD 
implantation to second echocardiographic examination 
was 32.71 ± 27.14 months. Subjective visual assessment 
of TR in four-grade scale was made by assessment of re-
trograde systolic flow from the right ventricle to the right 
atrium in transthoracic apical view. Worsening of TR was 
defined as its deterioration to higher grade (e.g. from grade 
II to grade III or IV). On this basis patients were divided 
into two groups. Patients with worsening of TR constituted 
TR+ group, patients without worsening of TR constituted 
TR– group.
Implantable cardioverter-defibrillator
The ICD interventions were classified as appropriate or 
inappropriate by experienced electrophysiologist on the 
basis of stored intracardiac electrograms.
Follow-up
Patients were seen in outpatient clinic every 6–12 months, 
according to clinical needs. When appropriate, information 
about outcome was obtained from patient’s physician or 
from members of his or her family.
Primary and secondary end-points
Primary end-points were cardiovascular death or orthotopic 
heart transplantation (OHT). Secondary end-points were 
adequate as well as inadequate interventions of ICD.
Statistical analysis
Mean ± standard deviation, total number and percentage 
were used to demonstrate the data. The t-Student test 
367www.journals.viamedica.pl/folia_cardiologica
Krzysztof Bernard Poślednik et al., Tricuspid regurgitation after ICD implantation in patients with ARVC
Table 1. Clinical, electrocardiographic (ECG) and echocardiogra-
phic (ECHO) characteristics of general study population
Parameter General 
study po­
pulation
Number of 
pts with lac­
king data
General characteristics
Males [%] 83 0
Mean age (years) 47 ± 13 0
Age at implantation (years) 40 ± 14 0
Pacemaker implanted [%] 23 0
Anamnesis before ICD implantation
Cardiac arrest [%] 31 0
Syncope [%] 69 0
Palpitations [%] 74 0
Family history of ARVC [%] 26 0
Signs and symptoms  
of heart failure [%]
49 0
RF ablation [%] 48 2
ECG parameters before ICD implantation
Epsilon waves [%] 56 8*
Echocardiogram findings
LV dysfunction [%]:
ECHO 1 43 0
ECHO 2 32 0
Mean LVEF [%]:
ECHO 1 59 ± 14 1
ECHO 2 57 ± 15 2
RV systolic dysfunction [%]:
ECHO 1 29 0
ECHO 2 43 0
RV enlargement** [%]:
ECHO 1 79 2
ECHO 2 86 0
RV borderline  
enlargement*** [%]:
ECHO 1 12 2
ECHO 2 11 0
ICD interventions
Adequate [%] 60 0
Inadequate [%] 29 0
*ECG parameters before ICD implantation in these pts were unavailable, **PLAX RVOT ≥ 32 mm; 
major diagnostic criterion (Revised [2010] task force criteria for diagnosis of ARVC); ***PLAX 
RVOT ≥ 29-31 mm; minor diagnostic criterion (Revised [2010] task force criteria for diagnosis of 
ARVC); pts — patients; ICD — implantable cardioverter-defibrillator; RF — radiofrequency; ARVC — 
arrhythmogenic right ventricular cardiomyopathy; LV — left ventricle; ECHO 1 — echocardiographic 
examination prior to ICD implantation; ECHO 2 — echocardiographic examination after ICD implan-
tation; LVEF — left ventricular ejection fraction; RV — right ventricle
and Wilcoxon test were used for continuous variables and 
the Fisher exact test for categorical variables. Statistical 
analysis was performed with SAS 9.2 software.
Results
Tricuspid regurgitation (Figure 1)
TR+ group was composed of 23 (65.71%) pts in whom 
the worsening of tricuspid regurgitation was found: 18 ma-
les (78.26%) and 5 females. Mean age in this group was 
46.13 ± 14.13 years. ICD was implanted in secondary 
prevention in 6 pts (26.09%).
TR– group included 12 pts without worsening of tricu-
spid regurgitation: 11 males (91.67%) and 1 female, mean 
age: 48.67 ± 12.47 years. ICD was implanted in secondary 
prevention in 5 pts (41.67%).
Signs and symptoms of heart failure
In TR+ group signs and symptoms of heart failure (HF) were 
present in 43.48% of patients before ICD implantation 
(17.39% in class III of New York Heart Association [NYHA] 
Functional Classification, 0 in class IV), and in 100% of pts 
in the follow-up (class III 21.74%, class IV 4.35%).
In TR– group signs and symptoms of HF were present 
in 58.33% of patients before ICD implantation (class III of 
NYHA 33.33%, class IV 8.33%) and in 91.67% of pts after 
ICD implantation (0 in class III, 16.67% in class IV).
Echocardiogram findings
In TR+ group, the mean PLAX RVOT was 37.43 ± 8.48 mm 
before ICD implantation and 42.52 ± 10.79 mm after the 
implantation.
Figure 1. Occurrence of tricuspid regurgitation in general study 
population; TR+ group with deterioration of tricuspid insufficiency 
after ICD implantation, TR– group with no worsening of tricuspid 
regurgitation
34.29%
TR+
65.71%
TR–
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In TR– group, the mean RVOT was 40.5±8.22 mm 
before ICD implantation, and 41.33 ± 6.02 mm after the 
procedure.
These results were statistically insignificant (p = 0.34 
and p = 0.68 for mean RVOT before and after ICD implan-
tation, respectively).
Worsening of TR was associated with dysfunction of 
the left ventricle (defined as ejection fraction < 55% or 
impaired contractility) in the follow-up echocardiogram; it 
was found in 9 patients (39.13%) in  TR+ group and only in 
2 (18.18%) patients in TR– group. However, these results 
were not statistically significant (p = 0.16).
Primary end-points (Figure 2)
During a follow-up of 91.06 ± 55.32 months there were 
4 deaths (11.43%), 3 due to heart failure and 1 non-cardiac 
(traffic accident). One (2.86%) patient underwent orthotopic 
heart transplantation.
In TR+ group 3 patients (13.04%) died — 2 (8.7%) pts 
due to HF.
In TR– group there was 1 (8.33%) cardiac death (be-
cause of HF) and 1 OHT (8.33%).
No SCD occurred during follow-up. Primary end-points 
data were not statistically significant.
Secondary end-points (Figure 3)
In TR+ group adequate interventions of ICD were found 
in 15 (65.22%) individuals, inadequate — in 9 (39.13%) 
patients.
In TR– group adequate interventions of ICD occurred 
in 6 pts (50%) and inadequate in 1 (8.33%).
P value for adequate interventions was 0.48, and for 
inadequate 0.11.
No ICD interventions occurred in 5 pts (21.74%) in TR+ 
group versus 6 (50%) in TR– group (p = 0.13).
Clinical characteristics in both study groups are pre-
sented in Table 2.
Discussion
The importance of tricuspid regurgitation in patients with 
ARVC after ICD implantation seems to be still under-recog-
nized. In Pinamonti et al. study [4] prevalence of significant 
tricuspid regurgitation was 15% in ARVC patients (with and 
without ICD or pacemaker). In medical literature available 
data are scarce.
Our study demonstrated that implantation of ICD can 
possibly worsen the tricuspid regurgitation. We didn’t prove 
that lead-induced TR in ARVC patients had negative impact 
on their prognosis, but we feel that a study with increased 
number of patients would have statistical power to prove 
otherwise.
The risk of lead-induced tricuspid regurgitation (LITR) 
should be taken into account in ARVC patients with ICD. Se-
vere TR is supposed to cause higher risk of cardiovascular 
death/OHT in patients with ARVC [4]. Potentially, it can cau-
se a necessity of valve repair or replacement — as described 
in a report of 41 such patients (six with an ICD); the mean 
time from device placement to surgery was 72 months 
(range 2 to 228 months) [7]. Several mechanisms may 
be involved in this entity. Perforation of the tricuspid valve 
(TV) leaflet by the intracardiac lead, entanglement of the 
lead with the TV, impingement of the TV leaflets, lead ad-
herence to the TV and chordal entanglement are reported 
among others [7–9]. Various studies show prevalence 
of LITR ranging from 7.2% to 39% [8]. This data scatter 
comes partially from different ways of TR assessment. In 
our study retrograde systolic flow from the right ventricle 
to the right atrium was assessed visually in transthoracic 
echocardiography and expressed in grades 1–4.
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Figure 2. Primary end-points (cardiac death or heart transplanta-
tion necessity) in TR+ and TR– group; results non-significant; TR+ 
group with deterioration of tricuspid insufficiency after ICD im-
plantation, TR– group with no worsening of tricuspid regurgitation
Figure 3. Secondary end-points – adequate ICD interventions in 
both study groups (TR+ and TR–); p = 0.48; TR+ group with deterio-
ration of tricuspid insufficiency after ICD implantation, TR– group 
with no worsening of tricuspid regurgitation
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In our study, worsening of tricuspid regurgitation 
occurred in 65.71% of study population (males 78.26%), 
probably due to ICD. This observation is crucial, because 
lead-induced TR is supposed to worsen the clinical outco-
me. Perhaps in the case of ARVC patients with indications 
for ICD implantation some alternative approaches should 
be considered, like placement of an epicardial ventricular 
lead or transvenous LV lead via the coronary sinus.
Table 2. Data of patients in both study groups (TR+ group with deterioration of tricuspid insufficiency after implantable cardioverter-defi-
brillator [ICD] implantation, TR– group with no worsening of tricuspid regurgitation)
Parameter TR+ group 
(n = 23)
TR– group 
(n = 12)
P value
General characteristics
Males [%] 78 92 NS
Mean age (years) 46.13 ± 14.13 48.67 ± 12.47 NS
Age at implantation (years) 39 ± 15 42 ± 13 NS
Pacemaker implanted (%) 26 17 NS
Anamnesis before ICD implantation
Cardiac arrest [%] 26 42 NS
Syncope [%] 61 83 NS
Palpitations [%] 74 75 NS
Family history of ARVC [%] 35 9 NS
Signs and symptoms of heart failure [%] 43 58 NS
RF ablation [%] 50 45 NS
ECG parameters
Epsilon waves [%] 53 63 NS
Echocardiogram findings
LV dysfunction [%]:
ECHO 1 39 50 NS
ECHO 2 39 18 NS
Mean LVEF [%]:
ECHO 1 58 ± 15 62 ± 10 NS
ECHO 2 55 ± 17 61 ± 11 NS
RV systolic dysfunction [%]:
ECHO 1 30 25 NS
ECHO 2 39 50 NS
RV enlargement* [%]:
ECHO 1 78 80 NS
ECHO 2 83 92 NS
RV borderline enlargement** [%]:
ECHO 1 9 20 NS
ECHO 2 13 8 NS
ICD interventions
Adequate [%] 65 50 NS
Inadequate [%] 39 8 NS
*PLAX RVOT ≥ 32 mm; major diagnostic criterion (Revised [2010] task force criteria for diagnosis of ARVC); **PLAX RVOT ≥ 29–31 mm; minor diagnostic criterion (Revised [2010] task force criteria for diag-
nosis of ARVC); NS — non-significant; ARVC — arrhythmogenic right ventricular cardiomyopathy; RF — radiofrequency; ECG — electrocardiography; LV — left ventricle; ECHO 1 — echocardiographic examination 
prior to ICD implantation; ECHO 2 — echocardiographic examination after ICD implantation; LVEF — left ventricular ejection fraction; RV — right ventricle
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Establishing our study we hypothesized that ICD (or 
CRT-D) implantation could have negative prognostic 
value for patients suffering from ARVC. According to this 
hypothesis, when the right ventricle is affected by the 
disease, LITR may cause its additional enlargement and 
remodeling translating into negative outcomes, such 
as heart failure, death or necessity of heart transplan-
tation. However, the study didn’t show statistical diffe-
rence between groups TR+ and TR- regarding primary 
end-points.
ICD interventions
Appropriate ICD interventions are believed to terminate 
arrhythmias, which otherwise might cause sudden car-
diac death [10]. We noticed discrepancy in the number of 
adequate ICD interventions between two groups. Namely, 
adequate ICD interventions happened more often in the 
group with TR deterioration in contrast to the second group 
(65.22% vs 50%).
On the other hand progressive tricuspid valve regur-
gitation could reflect the degree of overt cardiac muscle 
damage. That, in fact, could be responsible for increased 
number of ventricular arrhythmias due to macro-re-entry 
mechanism, marking a progression into ‘electrical’ phase 
of ARVC [1].
Left ventricle involvement
Left ventricle involvement is supposed to increase the risk 
of SCD [11].
In our study, 42.86% of patients presented with the 
involvement of the left ventricle by disease process in 
echocardiography examination before ICD implantation 
(defined as left ventricle ejection fraction below 55% or 
systolic impairment in echocardiographic examination). 
One study suggested that percentage of patients with CMR 
evidence of LV involvement may be as high as 84% [12]. 
This shows the necessity of broader consideration of ARVC 
as a disease of both ventricles.
Study limitations
First of all, it is difficult to establish whether TR worsening 
in ARVC is the result of LITR or just a natural course of 
the disease. However, we assume that LITR was a leading 
reason of TR worsening because mean time from ICD im-
plantation to control echocardiogram was relatively short 
(32.71 ± 27.14 months), probably inadequate for a consi-
derable progress of the disease.
The most important limitation of our study was small 
number of patients included into the study. We feel that 
because of this some of the data were statistically insig-
nificant.
ARVC is relatively rare disease and its first manifestation 
can be SCD or recurrent ventricular arrhythmia threatening 
one’s life. In some survivors of cardiac arrest ICD was im-
planted prior to detailed echocardiographic assessment 
and we had to exclude these patients from our study.
Conclusions
The study had no statistical power to prove that LITR is 
associated with worsening of the prognosis in patients with 
ARVC and high risk of sudden cardiac death. We assume 
that increased number of patients involved into the study 
would prove otherwise. Differences in outcome between 
both groups (with and without worsening of tricuspid re-
gurgitation) were statistically insignificant.
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Streszczenie
Wstęp. Problem niedomykalności zastawki trójdzielnej po implantacji elektrody prawokomorowej (LITR) u chorych 
z arytmogenną kardiomiopatią prawej komory (ARVC) nie został dostatecznie zbadany. U chorych obciążonych wysokim 
ryzykiem zdarzeń sercowych zwykle stosuje się wszczepialny kardiowerter-defibrylator (ICD) w ramach prewencji nagłego 
zgonu sercowego (SCD). Jednak uważa się, że wprowadzenie elektrody ICD do prawej komory może powodować pogor-
szenie niedomykalności zastawki trójdzielnej.
W związku z tym, że u wielu chorych konieczne jest wszczepienie ICD (lub urządzenia do terapii resynchronizującej serca) 
w ramach prewencji SCD autorzy postanowili ocenić częstość występowania LITR oraz rokowanie w tej grupie chorych.
Materiał i metody. Spośród 55 chorych z ARVC i ICD wszczepionym w ramach prewencji SCD autorzy wybrali 35 osób 
(średni wiek 48,78 ± 13,56 roku), w przypadku których dostępne były dane potrzebne do analizy. Na podstawie wyni-
ków echokardiografii badaną populację podzielono na dwie grupy: grupę TR+ obejmującą osoby, u których nastąpiło 
pogorszenie niewydolności zastawki trójdzielnej (TR) definiowane jako pogorszenie do wyższego stopnia, oraz grupę 
TR– (bez pogorszenia TR).
Wyniki. U 65,71% chorych nastąpiło pogorszenie TR po implantacji ICD. Średni czas obserwacji wynosił 91,06 ± 55,32 
miesiąca. W grupie TR+ 2 chorych (8,7%) zmarło z powodu niewydolności serca, a 1 chory zginął w wypadku komu-
nikacyjnym. W grupie TR– odnotowano zgon 1 chorego (8,33%) z powodu niewydolności serca, a 1 chorego poddano 
transplantacji serca (dane nieistotne statystycznie).
Wnioski. Autorzy nie wykazali, by pogorszenie TR wiązało się z gorszym efektem klinicznym. Potrzebne są dalsze badania 
w celu oceny wpływu LITR na rokowanie u chorych z ARVC, którym wszczepiono ICD.
Słowa kluczowe: arytmogenna kardiomiopatia prawej komory, niedomykalność zastawki trójdzielnej, wszczepialny 
kardiowerter-defibrylator, nagły zgon sercowy
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